Pacira BioSciences, Inc.

The regenerative medicine sector continues to seek increased contact with the US Food and Drug Administration, even as the architects of the Center for Biologics Evaluation and Research review structu

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January

Verona Pharma plc entered into agreements that give the company access to as much as $650m in new debt and other financing, bringing its new cash potential to more than $1bn after starting the year w

A fortnight or so after Vertex Pharmaceuticals Incorporated ’s VX-548 achieved one of the vanishingly few breakthroughs by a non-opioid painkiller, a start-up has emerged to develop a similarly actin